[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100594697":3},{"organization":4,"armGroups":7,"interventions":23,"overallOfficials":29,"centralContacts":34,"locations":40,"responsibleParty":58,"collaborators":29,"id":61,"slug":62,"hasResults":63,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":67,"eligibilityCriteria":68,"healthyVolunteers":63,"sex":69,"minAge":70,"maxAge":71,"enrollmentInfo":72,"targetDuration":29,"studyType":75,"phases":76,"briefSummary":78,"conditions":79,"keywords":82,"overallStatus":43,"whyStopped":29,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":97},{"fullName":5,"class":6},"Fatima Memorial Hospital","OTHER",[8,15,19],{"label":9,"type":10,"description":11,"interventionNames":12},"Low-Dose Dexmedetomidine","EXPERIMENTAL","Dexmedetomidine 0.2 µg\u002Fkg\u002Fhr + Ketamine 0.25 mg\u002Fkg\u002Fhr infusion",[13,14],"Drug: Dexmedetomidine","Drug: ketamine",{"label":16,"type":10,"description":17,"interventionNames":18},"Medium-Dose Dexmedetomidine","Dexmedetomidine 0.3 µg\u002Fkg\u002Fhr + Ketamine 0.25 mg\u002Fkg\u002Fhr infusion",[13,14],{"label":20,"type":10,"description":21,"interventionNames":22},"High-Dose Dexmedetomidine","Dexmedetomidine 0.4 µg\u002Fkg\u002Fhr + Ketamine 0.25 mg\u002Fkg\u002Fhr infusion",[13,14],[24,30],{"type":25,"name":26,"description":27,"armGroupLabels":28,"otherNames":29},"DRUG","Dexmedetomidine","Dexmedetomidine infusion at one of the following doses:\n\nGroup A: 0.2 µg\u002Fkg\u002Fhr Group B: 0.3 µg\u002Fkg\u002Fhr Group C: 0.4 µg\u002Fkg\u002Fhr Route of Administration: Intravenous Frequency: Continuous infusion during postoperative period",[20,9,16],null,{"type":25,"name":31,"description":32,"armGroupLabels":33,"otherNames":29},"ketamine","Ketamine infusion at a fixed dose of 0.25 mg\u002Fkg\u002Fhr administered in all three groups.\n\nRoute of Administration: Intravenous Frequency: Continuous infusion during postoperative period",[20,9,16],[35],{"name":36,"role":37,"phone":38,"phoneExt":29,"email":39},"Ahmed Naeem, MBBS","CONTACT","+923114681512","2505.ahmed@gmail.com",[41],{"facility":42,"status":43,"city":44,"state":45,"zip":46,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"Department of Anesthesiology, Fatima Memorial Hospital","RECRUITING","Lahore","Punjab Province","54000","Pakistan","PK",{"type":50,"coordinates":51},"Point",[52,53],74.35071,31.558,{"lat":53,"lon":52},[56],{"name":36,"role":57,"phone":29,"phoneExt":29,"email":29},"PRINCIPAL_INVESTIGATOR",{"type":57,"investigatorFullName":59,"investigatorTitle":60,"investigatorAffiliation":5,"oldNameTitle":29,"oldOrganization":29},"Ahmed Naeem","Principal Investigator","100594697","phase-4-comparison-of-dexmedetomidine--ketamine-for-postoperative-pain-in-c-section-100594697",false,"NCT07022821","Comparison of Dexmedetomidine + Ketamine for Postoperative Pain in C-Section","Comparison of Different Doses of Dexmedetomidine in Combination With Ketamine for Control of Post-Operative Pain in Lower Segment Caesarean Section Surgeries","KETODEX-CS","Inclusion Criteria:\n\n* Elective lower segment cesarean section\n* American Society of Anesthesiologists (ASA) Physical Status II\n* Provided informed consent\n\nExclusion Criteria:\n\n* Known drug allergy\n* Presence of significant comorbidities\n* Emergency surgery\n* Documented psychiatric illness","FEMALE","18 Years","50 Years",{"count":73,"type":74},90,"ESTIMATED","INTERVENTIONAL",[77],"PHASE4","This study aims to compare three different doses of dexmedetomidine, when combined with a fixed dose of ketamine, for pain control in women undergoing cesarean section. The goal is to find the most effective combination with the fewest side effects.",[80,81],"Postoperative Pain","Cesarean Section Pain",[83,84,85,26,86,87],"Cesarean Pain","Multimodal Analgesia","Spinal Anesthesia","Ketamine","Postoperative pain","2025-06-15",{"date":90,"type":91},"2025-06-18","ACTUAL",{"date":93,"type":91},"2025-05-16",{"date":95,"type":74},"2025-08-31",{"name":5,"class":6},1]